Response to Steele and Acheson
- PMID: 35538671
- DOI: 10.1111/dar.13478
Response to Steele and Acheson
References
-
- Steele M, Acheson LS. Commentary on “Opioid agonist treatment and client outcomes during the COVID-19 pandemic in south east Sydney, Australia”. Drug Alcohol Rev 2022;1020-2.
-
- Lintzeris N, Deacon RM, Hayes V et al. Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia. Drug Alcohol Rev 2022;41:1009-19.
-
- Lintzeris N, Hayed V, Arugoniri S. Interim guidance for the delivery of medication assisted treatment of opioid dependence in response to COVID-19: a national response. Sydney, Australia: RACP, 2020. Available at: https://www.racp.edu.au/docs/default-source/news-and-events/covid-19/int....
-
- NSW Department of Health. 2006. New South Wales Opioid Treatment Program. Clinical guidelines for methadone and buprenorphine treatment of opioid dependence. SHPN (MHDAO) 060160 ISBN 1741870070. Available at: https://www.scribd.com/document/294578891/GL2006-019 (accessed 14 April 2022).
-
- Australian Government Department of Health. Commonwealth Post-market Review of Opiate Dependence Treatment Program (ODTP) Medicines. Available at: https://www.pbs.gov.au/info/reviews/post-market-review-of-opiate-depende... (accessed 17 March 2022).
MeSH terms
LinkOut - more resources
Full Text Sources